Eema-FSH

How old is patient?
advertisement

Eema-FSH uses


1 INDICATIONS AND USAGE

Eema-FSH® is a gonadotropin indicated for:

1.1 Induction of Ovulation in Women who have Previously Received Pituitary Suppression

Prior to initiation of treatment with Eema-FSH®:

1.2 Development of Multiple Follicles as Part of an Assisted Reproductive Technology Cycle in Ovulatory Women Who Have Previously Received Pituitary Suppression

Prior to initiation of treatment with Eema-FSH®:

advertisement

2 DOSAGE AND ADMINISTRATION

Ovulation Induction


Assisted Reproductive Technology (ART) (2.3)

2.1 General Dosing Information

2.2 Recommended Dosing for Induction of Ovulation

The dosing scheme is stepwise and is individualized for each woman .

2.3 Recommended Dosing for Assisted Reproduction Technology (ART)

The recommended dosing scheme for patients undergoing IVF follows a stepwise approach and is individualized for each woman. The recommended initial dose of Eema-FSH® for women who have received a GnRH agonist for pituitary suppression is 225 International Units. Eema-FSH® may be administered together with MENOPUR® (menotropins for injection, USP), and the total initial dose when the products are combined should not exceed 225 International Units (150 International Units of Eema-FSH® and 75 International Units of MENOPUR® or 75 International Units of Eema-FSH® and 150 International Units of MENOPUR®).

advertisement

3 DOSAGE FORMS AND STRENGTHS

Lyophilized powder for Injection containing 82.5 International Units of FSH, to deliver 75 International Units of FSH after reconstituting with the diluent, supplied in sterile vials with diluent vials and Q-Cap® vial adapters.

Lyophilized powder for injection: containing 82.5 International Units of FSH, to deliver 75 International Units FSH after reconstituting, supplied as lyophilized powder in sterile vials with diluent vials. (3)

4 CONTRAINDICATIONS

Eema-FSH® is contraindicated in women who exhibit:


Eema-FSH® is contraindicated in women who exhibit:

advertisement

5 WARNINGS AND PRECAUTIONS

Eema-FSH® should only be used by physicians who are experienced in infertility treatment. Eema-FSH® contains gonadotropic substances capable of causing in women, Ovarian Hyperstimulation Syndrome [OHSS] with or without pulmonary or vascular complications and multiple births . Gonadotropin therapy requires the availability of appropriate monitoring facilities . Use the lowest effective dose.

5.1 Hypersensitivity and Anaphylactic Reactions

Hypersensitivity/anaphylactic reactions associated with urofollitropins for injection, purified administration have been reported in some patients. These reactions presented as generalized urticaria, facial edema, angioneurotic edema, and/or dyspnea suggestive of laryngeal edema. The relationship of these symptoms to uncharacterized urinary proteins is uncertain.

5.2 Abnormal Ovarian Enlargement

In order to minimize the hazard associated with abnormal ovarian enlargement that may occur with Eema-FSH® therapy, the lowest effective dose should be used . Use of ultrasound monitoring of ovarian response and/or measurement of serum estradiol levels is important to minimize the risk of ovarian stimulation .

If the ovaries are abnormally enlarged on the last day of Eema-FSH® therapy, hCG should not be administered in order to reduce the chances of development of the Ovarian Hyperstimulation Syndrome . Prohibit intercourse in women with significant ovarian enlargement because of the danger of hemoperitoneum resulting from rupture of ovarian cysts .

5.3 Ovarian Hyperstimulation Syndrome (OHSS)

OHSS: OHSS is a medical event distinct from uncomplicated ovarian enlargement. OHSS may progress rapidly to become a serious medical event. It is characterized by an apparent dramatic increase in vascular permeability, which can result in a rapid accumulation of fluid in the peritoneal cavity, thorax, and potentially, the pericardium. The early warning signs of development of OHSS are severe pelvic pain, nausea, vomiting, and weight gain. Abdominal pain, abdominal distension, gastrointestinal symptoms including nausea, vomiting and diarrhea, severe ovarian enlargement, weight gain, dyspnea, and oliguria have been reported with OHSS. Clinical evaluation may reveal hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic events . Transient liver function test abnormalities suggestive of hepatic dysfunction, which may be accompanied by morphologic changes on liver biopsy, have been reported in association with OHSS.

OHSS occurs after treatment has been discontinued and reaches its maximum at about 7 to 10 days after treatment. Usually, OHSS resolves spontaneously with the onset of menses. If there is evidence that OHSS may be developing prior to hCG administration , the hCG must be withheld.

Cases of OHSS are more common, more severe and more protracted if pregnancy occurs. OHSS develops rapidly; therefore patients should be followed for at least two weeks after hCG administration.

If severe OHSS occurs, gonadotropins, including hCG, must be stopped and consideration should be given as to whether the woman needs be hospitalized. Treatment is primarily symptomatic and overall should consist of bed rest, fluid and electrolyte management, and analgesics (if needed). Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. The management of OHSS may be divided into three phases as follows:


Do not remove ascitic, pleural, and pericardial fluid unless there is the necessity to relieve symptoms such as pulmonary distress or cardiac tamponade.

OHSS increases the risk of injury to the ovary. Pelvic examination or intercourse may cause rupture of an ovarian cyst, which may result in hemoperitoneum, and should be avoided.

If bleeding occurs and requires surgical intervention, the clinical objective should be to control the bleeding and retain as much ovarian tissue as possible. A physician experienced in the management of this syndrome, or who is experienced in the management of fluid and electrolyte imbalances, should be consulted.

In a clinical study of induction of ovulation indication, 6 of 72 (8.33%) Eema-FSH® treated women developed OHSS and 2 were classified as severe. In a clinical study for the development of multiple follicles as part of an IVF cycle, 3 of 60 women treated with Eema-FSH® developed OHSS and 1 was classified as severe.

5.4 Pulmonary and Vascular Complications

Serious pulmonary conditions have been reported in women treated with gonadotropins. In addition, thromboembolic events both in association with, and separate from, the Ovarian Hyperstimulation Syndrome have been reported in women treated with gonadotropins. Intravascular thrombosis and embolism, which may originate in venous or arterial vessels, can result in reduced blood flow to critical organs or the extremities. Women with generally recognized risk factors for thrombosis, such as personal or family history, severe obesity, or thrombophilia, may have an increased risk of venous or arterial thromboembolic events during or following treatment with gonadotropins. Sequelae of such reactions have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb and rarely in myocardial infarctions. In rare cases, pulmonary complications and/or thromboembolic events have resulted in death. In women with recognized risk factors, the benefits of ovulation induction and assisted reproductive technology need to be weighed against the risks. Pregnancy also carries an increased risk of thrombosis.

5.5 Ovarian Torsion

Ovarian torsion has been reported after treatment with gonadotropins. This may be related to OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries. Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion.

5.6 Multi-fetal Gestation and Birth

Multi-fetal gestation and births have been reported with all gonadotropin therapy including therapy with Eema-FSH®.

In a controlled study of 72 patients undergoing induction of ovulation, 66.7% of pregnancies of women treated with subcutaneous Eema-FSH® were multiples, while 28.6% of pregnancies in women treated with intramuscular Eema-FSH® were multiples.

In a controlled study of 60 patients undergoing IVF, 34.8% of pregnancies of women treated with subcutaneous Eema-FSH® were multiples.

Before beginning treatment with Eema-FSH®, advise the woman and her partner of the potential risk of multi-fetal gestation and birth.

5.7 Congenital Malformations

The incidence of congenital malformations after some ART [specifically in vitro fertilization or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI. There are no indications that the use of gonadotropins during IVF or ICSI is associated with an increased risk of congenital malformations.

5.8 Ectopic Pregnancy

Since infertile women undergoing ART often have tubal abnormalities, the incidence of ectopic pregnancy may be increased. Early confirmation of intrauterine pregnancy should be determined by β-hCG testing and transvaginal ultrasound.

5.9 Spontaneous Abortion

The risk of spontaneous abortion is increased with gonadotropin products. However, causality has not been established. The increased risk may be a factor of the underlying infertility.

5.10 Ovarian Neoplasms

There have been infrequent reports of ovarian neoplasms, both benign and malignant, in women who have had multiple drug therapy for controlled ovarian stimulation; however, a causal relationship has not been established.

5.11 Laboratory Tests

In most instances, treatment of women with Eema-FSH® will result only in follicular growth and maturation. In the absence of an endogenous LH surge, hCG is given when monitoring of the woman indicates that sufficient follicular development has occurred. This may be estimated by ultrasound alone or in combination with measurement of serum estradiol levels. The combination of both ultrasound and serum estradiol measurement are useful for monitoring follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement and minimizing the risk of the Ovarian Hyperstimulation Syndrome and multiple gestation.

The clinical confirmation of ovulation is obtained by direct or indirect indices of progesterone production as well as sonographic evidence of ovulation.

Direct or indirect indices of progesterone production:


Sonographic evidence of ovulation:

advertisement

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed elsewhere in the labeling:


To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc. at 1-888-FERRING (1-888-337-7464) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.

The safety of Eema-FSH® was examined in four clinical studies that enrolled a total of 222 women who received Eema-FSH®.

Ovulation Induction

In a randomized, multi-center, active controlled study, a total of 72 women received Eema-FSH® (35 in a subcutaneous administration arm and 37 in an intramuscular administration arm) for induction of ovulation. Adverse reactions occurring at an incidence of ≥2% incidence in women receiving Eema-FSH® are shown in Table 1.

All Patients with Adverse Events ≥ 2%
Adverse Events (%) Eema-FSH® subcutaneous Eema-FSH® intramuscular
N=35 N=37
Genitourinary/Reproductive
OHSS 4 (11.4) 2 (5.4)
Vaginal Hemorrhage 3 (8.6) 0 (0.0)
Ovarian Disorder (Pain, Cyst) 1 (2.9) 3 (8.1)
Urinary tract infection 0 1 (2.7)
Cervix disorder 1 (2.9) 0
Gastrointestinal
Nausea 2 (5.7) 0 (0.0)
Enlarged Abdomen 1 (2.9) 1 (2.7)
Abdominal Pain 1 (2.9) 2 (5.4)
Vomiting 0 1 (2.7)
Constipation 0 1 (2.7)
Diarrhea 0 1 (2.7)
Metabolic/Nutritional
Dehydration 0 1 (2.7)
Weight gain 1 (2.9) 0
Skin/Appendages
Acne 1 (2.9) 0
Exfoliative dermatitis 0 1 (2.7)
Other Body Systems
Headache 4 (11.4) 3 (8.1)
Pain 2 (5.7) 0 (0.0)
Neck pain 0 1 (2.7)
Respiratory Disorder 2 (5.7) 0 (0.0)
Hot Flashes 2 (5.7) 0 (0.0)
Fever 0 1 (2.7)
Hypertension 0 1 (2.7)
Emotional lability 0 1 (2.7)
Depression 0 1 (2.7)
Accidental injury 0 1 (2.7)

Assisted Reproductive Technology

Three studies examined the safety profile of Eema-FSH® in ART. A total of 150 women received treatment with Eema-FSH® in these studies. Adverse reactions occurring at an incidence of ≥2% incidence for this integrative assessment are presented in Table 2.

All Patients with Adverse Events ≥ 2%
Adverse Events (%) Eema-FSH® subcutaneous
N=150
Genitourinary/Reproductive
Vaginal hemorrhage 7 (4.7)
Post retrieval pain 12 (8.0)
Pelvic pain/cramps 10 (6.7)
OHSS 9 (6.0)
Uterine spasms 4 (2.7)
Vaginal spotting 4 (2.7)
Urinary tract infection 5 (3.3)
Ovarian disorder 3 (2.0)
Breast tenderness 3 (2.0)
Vaginal Discharge 4 (2.7)
Infection fungal 3 (2.0)
Gastrointestinal
Abdominal cramps 21 (14.0)
Nausea 13 (8.7)
Abdominal pain 7 (4.7)
Abdominal fullness/enlargement 10 (6.7)
Constipation 3 (2.0)
Other Body Systems
Headache 19 (12.7)
Pain 8 (5.3)
Rash 4 (2.7)
Respiratory disorder 6 (4.0)
Sinusitis 3 (2.0)
Injection site reaction 6 (4.0)
Hot flash 6 (4.0)
Emotional lability 3 (2.0)

6.2 Postmarketing Experience

The following adverse reactions have been reported during postmarketing use of gonadotropins. Because these reactions were reported voluntarily from a population of uncertain size, the frequency or a causal relationship to Eema-FSH® cannot be reliably determined.

7 DRUG INTERACTIONS

No drug/drug interaction studies in humans have been conducted for Eema-FSH®.

No drug/drug interaction studies have been conducted for Eema-FSH® in humans (7)

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic effects

Pregnancy Category X .

8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in the nursing infant from Eema-FSH®, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.6 Renal and Hepatic Insufficiency

Safety and effectiveness in women with renal and hepatic sufficiency have not been established.

10 OVERDOSAGE

Aside from possible ovarian hyperstimulation and multiple gestations , little is known concerning the consequences of acute overdosage with Eema-FSH®.

11 DESCRIPTION

Eema-FSH® is a product containing a highly purified preparation of human follicle stimulating hormone (hFSH) extracted from the urine of postmenopausal women. Human FSH is a gonadotropin and consists of two non-covalently linked glycoproteins designated as the α and β subunits. The α subunit has 92 amino acids of which two are modified by attachment of carbohydrates. The β subunit has 111 amino acids of which two are modified by attachment of carbohydrates.

Eema-FSH® is a sterile, lyophilized powder intended for subcutaneous or intramuscular injection after reconstitution with sterile 0.9% Sodium Chloride Injection, USP. Each vial of Eema-FSH® contains 82.5 International Units (IU) of Follicle Stimulating Hormone (FSH) activity, 23 mg Lactose Monohydrate, 0.005 mg Polysorbate 20, and Sodium Phosphate buffer (Sodium Phosphate dibasic, Heptahydrate and Phosphoric acid) for pH adjustments, which, when reconstituted with diluent, will deliver 75 International Units of FSH. Eema-FSH® contains up to 2% luteinizing hormone (LH) activity based on bioassay. Human Chorionic Gonadotropin (hCG) is not detected in Eema-FSH®. When stored at 3° to 25°C, up to 40% of the α-subunits may be oxidized.

The in vivo biological activity of Eema-FSH for injection, purified is determined by using reference standards calibrated against the First International Standard for follicle-stimulating hormone, (FSH, Eema-FSH), Urinary, Human for Bioassay, National Institute for Biological Standards and Control (NIBSC) at its 46th meeting in 1995.

FSH is a glycoprotein that is acidic and water-soluble.

Eema-FSH® has been mixed in vitro with MENOPUR® with no evidence of aggregation.

Therapeutic class: Infertility

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Eema-FSH® administered for 7 to 12 days produces ovarian follicular growth in women who do not have primary ovarian failure. Treatment with Eema-FSH® in most instances results only in follicular growth and maturation. When sufficient follicular maturation has occurred, hCG must be given to induce ovulation.

12.3 Pharmacokinetics

Single doses of 225 International Units and multiple daily doses (7 days) of 150 International Units of Eema-FSH® were administered to healthy volunteer female subjects while their endogenous FSH was suppressed. Sixteen subjects received Eema-FSH® subcutaneously and 12 received the drug intramuscularly. Serum FSH concentrations were determined. Based on the steady state ratio of FSH Cmax and AUC, subcutaneous and intramuscular administration of Eema-FSH® were not bioequivalent. Multiple doses of Eema-FSH® intramuscular resulted in Cmax and AUC of 77.7% and 81.8% compared to multiple doses of Eema-FSH® subcutaneous. The FSH pharmacokinetic parameters for single and multiple dose Eema-FSH®, administered subcutaneously and intramuscularly are in Table 3.

Single Dose (225 IU) Multiple Dose × 7 (150 IU)
PK Parameters Subcutaneous Intramuscular Subcutaneous Intramuscular
Cmax (mIU/mL) 6.0 (1.7) 8.8 (4.5) 14.8 (2.9) 11.5 (2.9)
Tmax (hrs) 20.5 (7.7) 17.4 (12.2) 9.6 (2.1) 11.3 (8.4)
AUCobs (mIU∙hr/mL) 379 (111) 331 (179) 234.7 (77.0) 192.1 (52.3)
t1/2 (hrs) 31.8 37 20.6 15.2

Absorption

The subcutaneous route of administration trends toward greater bioavailability than the IM route for single and multiple doses of Eema-FSH®.

Distribution

Human tissue or organ distribution of FSH has not been studied for Eema-FSH®.

Metabolism

Metabolism of FSH has not been studied for Eema-FSH® in humans.

Elimination

The mean elimination half-lives of FSH for subcutaneous and intramuscular single dosing are 31.8 and 37 hours, respectively. However, following multiple dosing (× 7 days) they are 20.6 and 15.2 hours for SC and IM, respectively.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term toxicity studies in animals and in vitro mutagenicity tests have not been performed to evaluate the carcinogenic potential of Eema-FSH for injection, purified.

14 CLINICAL STUDIES

The efficacy of Eema-FSH® was examined in two clinical studies, one for in-vitro fertilization and one for ovulation induction (OI).

14.1 Ovulation Induction

In the randomized, multi-center, active-controlled, ovulation induction study, women underwent pituitary suppression with a GnRH agonist before being randomized to subcutaneously administered Eema-FSH® , intramuscularly-administered Eema-FSH®, or a subcutaneously administered commercial recombinant FSH product. A total of 111 oligo-anovulatory women were randomized to both treatment arms, of which 72 received Eema-FSH®, starting at a dose of 150 International Units daily for 5 days. Subsequently each woman received individual titration of the Eema-FSH® dose from 75 to 450 International Units daily based on ultrasound and estradiol (E2) levels. The total duration of dosing did not exceed 12 days. Results for the Intent-To-Treat Population are summarized in Table 4.

Eema-FSH® Subcutaneous Eema-FSH® Intramuscular
Parameter N=35 N=37
Ovulation (%) 24 (68.6) 26 (70.3)
Received hCG (%) 25 (71.4) 28 (75.7)
Mean Peak Serum E2 (pg/mL) (SD) 976.5 (680.6) 893.2 (815.2)
Chemical Pregnancy (%) 11 (31.4) 8 (21.6)
Clinical Pregnancy (%) 9 (25.7) 7 (18.9)
Continuing Pregnancy (%) 9 (25.7) 7 (18.9)
Pts. w/Live Births (%) 9 (25.7) 6 (16.2)

14.2 Assisted Reproductive Technologies [ART]

In the randomized, multi-center, active-controlled, IVF study, women underwent pituitary suppression with a GnRH agonist before being randomized to subcutaneously administered Eema-FSH® or a subcutaneously administered commercial recombinant FSH product. A total of 120 patients were randomized to both treatment arms, of which 60 received Eema-FSH®, starting at a dose of 225 International Units daily for 5 days. Subsequently each woman received individual titration of the dose from 75 to 450 International Units daily based on ultrasound and estradiol (E2) levels. The total duration of dosing did not exceed 12 days. Results are summarized in Table 5 for the Intent-To-Treat population.

Eema-FSH® subcutaneous
Parameter n=60
Mean Total Oocytes Retrieved Per Patient (SD) 11.8 (6.3)
Mean Mature Oocytes Retrieved Per Patient (SD) 9.0 (5.7)
Patients with Oocyte Retrieval (%) 57 (95.0)
Patients with Embryo Transfer (%) 57 (95.0)
Patients with Chemical Pregnancy (%) 28 (46.6)
Patients with Clinical Pregnancy (%) 25 (41.7)
Patients with Continuing Pregnancy (%) 23 (38.3)

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Eema-FSH® is supplied in a sterile, lyophilized, single dose vial containing 82.5 International Units of FSH, to deliver 75 International Units FSH after reconstituting with the diluent.

Each vial is available with an accompanying vial of sterile diluent containing 2 mL of 0.9% Sodium Chloride Injection, USP.

75 International Units FSH activity, supplied as:

NDC 55566-8505-6: Box of 5 vials + 5 vials diluent + 5 Q-Cap® vial adaptors.

16.2 Storage and Handling

Lyophilized powder may be stored refrigerated or at room temperature (3° to 25° C/37° to 77°F). Protect from light. Use immediately after reconstitution. Discard unused material.

17 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling

17.1 Dosing and Use

Instruct women on the correct usage and dosing of MENOPUR® . Caution women not to change the dosage or the schedule of administration unless she is told to do so by her healthcare provider.

17.2 Duration and Monitoring Required

Prior to beginning therapy with Eema-FSH®, inform women about the time commitment and monitoring procedures necessary for treatment.

17.3 Instructions Regarding a Missed Dose

Inform the woman that if she misses or forgets to take a dose of Eema-FSH®, the next dose should not be doubled and she should call her healthcare provider for further dosing instructions.

17.4 Ovarian Hyperstimulation Syndrome

Inform women regarding the risks of OHSS and OHSS-associated symptoms including lung and blood vessel problems and ovarian torsion with the use of Eema-FSH®.

17.5 Multi-fetal Gestation and Birth

Inform women regarding the risk of multi-fetal gestation and birth with the use of Eema-FSH® .

Vials of sterile diluent of 0.9% Sodium Chloride Injection, USP, manufactured for Ferring Pharmaceuticals Inc.

MANUFACTURED FOR:


Step 1. Preparing your Eema-FSH® or Eema-FSH® mixed with MENOPUR®.


If your healthcare provider tells you to use more than 1 vial of Eema-FSH® or tells you to mix your Eema-FSH® with MENOPUR® in the same syringe:


Step 2. Removing the Q-Cap® and adding your needle for injection.


Step 3. Prepare Injection site for Eema-FSH® or with Eema-FSH® mixed with MENOPUR®.

Step 4: Injection

Step 5. After your injection.

Step 6. Disposing of your used needles and syringes.


Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

MANUFACTURED FOR:

FERRING PHARMACEUTICALS INC.

PARSIPPANY, NJ 07054

Revised: July 2015

Figure A Figure B Figure C Figure D Figure E Figure F Figure G Figure H Figure I Figure J Figure K Figure L Figure M Figure N Figure O Figure P Figure Q Figure R Figure S Figure T Figure U Figure V Figure W Figure X Figure Y Figure Z Figure AA Logo

Eema-FSH pharmaceutical active ingredients containing related brand and generic drugs:

Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.


Eema-FSH available forms, composition, doses:

Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.


Eema-FSH destination | category:

Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.


Eema-FSH Anatomical Therapeutic Chemical codes:

A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.


Eema-FSH pharmaceutical companies:

Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.


advertisement

References

  1. Dailymed."BRAVELLE (UROFOLLITROPIN) KIT [FERRING PHARMACEUTICALS INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Eema-FSH?

Depending on the reaction of the Eema-FSH after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Eema-FSH not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Eema-FSH addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Eema-FSH, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Eema-FSH consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

Visitor reported doses

No survey data has been collected yet

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 29 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology

© 2002 - 2024 "sdrugs.com". All Rights Reserved